Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement
Executive Summary
What was AstraZeneca's trash is now Ironwood's treasure, as it pays $100m up front, along with milestones and royalties, to acquire gout drug approved in December, but not yet launched.
You may also be interested in...
Ironwood Pulls Plug On Struggling Gout Drug Zurampic
Due to poor sales, the drug, which AstraZeneca picked up through its $1.26bn acquisition of Ardea, is now being terminated in the US. Ironwood, already in the process of splitting up, is going to focus on its core gastrointestinal franchise.
ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III
The ACR/ARHP Annual Meeting in San Diego offered new details from studies of new and existing therapies across a range of rheumatic diseases, from rheumatoid arthritis to rare diseases. Scrip shares notes here from interviews with Lilly, Ironwood, Corbus and Samumed.
Duzallo Approval Opens Gout Opportunity For Ironwood
Pricing for Duzallo, a fixed-dose combination of Zurampic (lesinurad) with generic allopurinol, will likely be on par with Zurampic's solo price tag of $371 per month to smooth the way with payers.